Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
1.020
-0.040 (-3.77%)
Nov 7, 2025, 4:00 PM EST - Market closed
Scinai Immunotherapeutics Revenue
Scinai Immunotherapeutics had revenue of $386.50K in the quarter ending June 30, 2025, with 36.09% growth. This brings the company's revenue in the last twelve months to $1.15M, up 303.87% year-over-year. In the year 2024, Scinai Immunotherapeutics had annual revenue of $658.00K.
Revenue (ttm)
$1.15M
Revenue Growth
+303.87%
P/S Ratio
1.17
Revenue / Employee
$37,000
Employees
31
Market Cap
3.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 658.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SCNI News
- 4 weeks ago - Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities - PRNewsWire
- 2 months ago - Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - PRNewsWire
- 3 months ago - Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - PRNewsWire
- 5 months ago - Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 - PRNewsWire
- 5 months ago - Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - PRNewsWire
- 5 months ago - Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn - PRNewsWire
- 6 months ago - Scinai Announces Annual Financial Results for 2024 - PRNewsWire
- 6 months ago - Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases - PRNewsWire